Celltrion Gears Up For Phase III Trial For Biosimilar Of Roche’s Rituxan
This article was originally published in PharmAsia News
Korea’s Celltrion said it is on path to a new Phase III trial design of a biosimilar of Roche’s Rituxan after presenting positive Phase I trial data in San Diego in late October.
You may also be interested in...
Morningstar expects 229% revenue growth during the 2015-2020 period for BioMarin, far stronger than larger competitors. Virology powerhouse Gilead is the only one of the 20 largest biopharmas expected to face a decline in revenue over the period.
The company has biosimilars of Rituxan, Herceptin and Remicade in clinical trials and a biosimilar to Humira is about to enter Phase I; Pfizer is pursuing the biosimilar pathway for all of its candidates.
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.